They stated that it would be a controlled launch which sounds to me like they will not outsell their supply. As production increases they will aptly target and increase their geographical footprint. Just my thoughts.
At least his posts are entertaining. Your's are not.
That's Barron's forecast? They are as misinformed as the person who asked Al, "how Afrezza is different than Exhubra" at the cc. These people are either ignorant or intentionally misleading.
Did I hear in the cc that the $150,000,000 and future milestone payments will eventually be applied as earning only after there is a steady stream of sales? If so, that will exaggerate earnings to the upside when that time comes. Combine that eventual occurrence with the 80,000,000 shares short that will have to eventually cover.......Hmmm.
Correct! Afrezza's nich market are only the type 1 and type 2 diabetics that eat. So yes, I agree it's market is limited by those parameters.
Do you think Dianne Palumbo knows any more about what happened at that meeting than you or I? I don't.
I don't know if it's true but I read on this board that SNY has 30,500 sales reps. If true, each would have to convert 16 patients to switch to Affreza in order to reach the 500k patients. I'd say that is in the relm of possibility.
Itt's a start but I believe the % of physicians with a preference for Afrezza over other options will increase rapidly with each satisfied user.
I don't get why you say quiet period. I listened to the cc and management stated clearly the plan of action and reported that they accomplished everything they said they would up to date. No secrets, no conspiracies, everything according to the plan that's been stated all along. Stop listening to the delusional few posting here and accept the fact that bringing a revolutionary drug to a population of hundreds of millions takes time.
I think a few players are going to decide they worked this one enough and start covering, today could be the the day starting at 2:00. If not today then soon......JMO
In order to close their position, 78,000,000 share must be purchased. I'd say that qualifies as a catalyst.
Legitimate answers please.
1. Is there a faster acting insulin available on the market?
2. Is there an insulin with a shorter tail on the market?
3. Is there a delivery method for fast acting insulin other than A that doesn't require injecting(of course many here think injecting before every meal is no big deal. I disagree).
4. is there a better suited partner to launch a diabetes drug globally than SNY?
5. Is the diabetes market really growing at the rate being claimed by the WHO?
6. Is it true people don't mind injecting themselves day in and day out?
Disappointed that Mnkd partnered ther the global driving force in diabetes management.......you're hard to please.